Patents Assigned to CYTLIMIC INC.

PHARMACEUTICAL COMPOSITION

Publication number: 20220401540

Abstract: The present invention provides a novel technology useful for a cancer vaccine therapy, that is, a pharmaceutical composition wherein a Toll-like receptor agonist, LAG-3 protein, a variant thereof or a derivative thereof, at least one immunogenic agent, and an immune checkpoint inhibitor are administered in combination.

Type: Application

Filed: November 26, 2020

Publication date: December 22, 2022

Applicant: CYTLIMIC INC.

Inventors: Shun DOI, Yoshihide SEGAWA, Koji TAMADA, Hiroaki NAGANO, Shoichi HAZAMA
Composition comprising poly I:C and LAG-3-IGG fusion protein

Patent number: 11491204

Abstract: The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Grant

Filed: July 22, 2020

Date of Patent: November 8, 2022

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
HSP70-DERIVED PEPTIDE, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN PRESENTING CELL

Publication number: 20220193213

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Type: Application

Filed: March 11, 2022

Publication date: June 23, 2022

Applicant: CYTLIMIC INC.

Inventors: Tomoya MIYAKAWA, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEIN

Publication number: 20220175915

Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Application

Filed: February 25, 2022

Publication date: June 9, 2022

Applicant: CYTLIMIC INC.

Inventors: Tomoya MIYAKAWA, Shun DOI, Koji TAMADA
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

Patent number: 11304997

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Type: Grant

Filed: December 16, 2019

Date of Patent: April 19, 2022

Assignee: CYTLIMIC INC.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

Patent number: 11291718

Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Grant

Filed: April 14, 2017

Date of Patent: April 5, 2022

Assignee: CYTLIMIC INC.

Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
MEDICINE

Publication number: 20210000916

Abstract: The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Application

Filed: July 22, 2020

Publication date: January 7, 2021

Applicant: CYTLIMIC INC.

Inventors: Tomoya MIYAKAWA, Shun DOI, Koji TAMADA
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

Patent number: 10875900

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Grant

Filed: February 5, 2020

Date of Patent: December 29, 2020

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein

Patent number: 10842848

Abstract: The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Grant

Filed: April 7, 2016

Date of Patent: November 24, 2020

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Shun Doi, Koji Tamada
PEPTIDE DERIVED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS

Publication number: 20200157163

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Application

Filed: February 5, 2020

Publication date: May 21, 2020

Applicant: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
HSP70-DERIVED PEPTIDE, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELL

Publication number: 20200121772

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Type: Application

Filed: December 16, 2019

Publication date: April 23, 2020

Applicant: CYTLIMIC INC.

Inventors: Tomoya Miyakawa, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

Patent number: 10590179

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Grant

Filed: November 9, 2018

Date of Patent: March 17, 2020

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
MEDICINE

Publication number: 20200038508

Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Application

Filed: April 14, 2017

Publication date: February 6, 2020

Applicant: CYTLIMIC INC.

Inventors: Tomoya MIYAKAWA, Shun DOI, Koji TAMADA
HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

Patent number: 10537626

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Type: Grant

Filed: October 7, 2015

Date of Patent: January 21, 2020

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells

Patent number: 10526388

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Grant

Filed: March 9, 2016

Date of Patent: January 7, 2020

Assignee: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
PEPTIDE DERIVED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS

Publication number: 20190062389

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Application

Filed: November 9, 2018

Publication date: February 28, 2019

Applicant: CYTLIMIC INC.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
HSP70-Derived Peptide, Pharmaceutical Composition for Treating or Preventing Cancer Using Same, Immunity Inducer, and Method for Producing Antigen Presenting Cell

Publication number: 20180169199

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Type: Application

Filed: October 7, 2015

Publication date: June 21, 2018

Applicant: Cytlimic Inc.

Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
PEPTIDE DERIVED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER USING THE SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS

Publication number: 20180105567

Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Type: Application

Filed: March 9, 2016

Publication date: April 19, 2018

Applicant: CYTLIMIC INC,

Inventors: Tomoya MIYAKAWA, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
MEDICINE

Publication number: 20180071362

Abstract: The present invention provides a medicine containing a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.

Type: Application

Filed: April 7, 2016

Publication date: March 15, 2018

Applicant: CYTLIMIC INC.

Inventors: Tomoya MIYAKAWA, Shun DOI, Koji TAMADA